Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL3 | Q96JM7 | 8/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.41 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21610969 | 0.93 | CYP1A2 (0.53) | CYP1A2TDP1L3MBTL3L3MBTL1ACHE | |
| SCHEMBL4072905 | 0.92 | CYP1A2 (0.61) | CYP1A2TDP1L3MBTL3L3MBTL1ACHE | |
| SCHEMBL23269622 | 0.90 | CYP1A2 (0.59) | CYP1A2TDP1L3MBTL3L3MBTL1ACHE | |
| SCHEMBL27932674 | 0.86 | L3MBTL3 (0.53) | CYP1A2TDP1L3MBTL3L3MBTL1ACHE | |
| SCHEMBL2856149 | 0.84 | L3MBTL3 (0.51) | CYP1A2TDP1L3MBTL3L3MBTL1ACHE | |
| SCHEMBL3938492 | 0.83 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL13207179 | 0.83 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1EPHX2MBTD1EPHX1 | |
| SCHEMBL15508283 | 0.83 | CYP1A2 (0.52) | CYP1A2TDP1L3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL12881316 | 0.82 | L3MBTL3 (0.50) | TDP1L3MBTL3L3MBTL1ACHEALDH1A1 | |
| SCHEMBL14899995 | 0.82 | L3MBTL3 (0.50) | CYP1A2TDP1L3MBTL3L3MBTL1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248740-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | NATIONAL CANCER CENTER (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230248740-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | NATIONAL CANCER CENTER (KR) | 2023-08-10 | — | — | US | disclosed |
| EP-3828185-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20200253981-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2020-08-13 | — | — | US | disclosed |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-07-30 | — | — | US | disclosed |
| EP-3604304-A1 | PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018174650-A9 | PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES | 재단법인 대구경북첨단의료산업진흥재단 | 2020-01-02 | — | — | WO | disclosed |
| EP-3536323-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | Dana Farber Cancer Institute, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| WO-2018075608-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| WO-2018053373-A1 | USES OF SATL-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2018-03-22 | — | — | WO | disclosed |
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-19 | — | — | US | disclosed |
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-19 | — | — | US | disclosed |
| US-8637542-B2 | Kinase inhibitors and methods of use | INTELLIKINE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| US-7897603-B2 | Selected CGRP-antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| WO-2010080712-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INSTITUTE (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-2119706-A1 | PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE | Eisai R&D Management Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-20090182142-A1 | Aromatic Compound | FURUKUBO SHIGERU | 2009-07-16 | — | — | US | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| WO-2007036532-A2 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, BRSK1, TAOK3 | CYP1A2 3934/4885TDP1 823/4885L3MBTL3 1904/4885 |
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | GCKR, GRK4, GRK5 | CYP1A2 4066/4885TDP1 4161/4885L3MBTL3 4648/4885 |
| US-20200253981-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | SIK2, SIK1, SIK3 | CYP1A2 3051/4885TDP1 2225/4885L3MBTL3 4457/4885 |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | CXCR4, CXCL12, CXCR1 | CYP1A2 2440/4885TDP1 4045/4885L3MBTL3 4642/4885 |
| US-20230248740-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | LRRK2, FABP7, PARK7 | CYP1A2 4585/4885TDP1 921/4885L3MBTL3 1291/4885 |
| US-20090182142-A1 | Aromatic Compound | HRH4, CCR4, HRH3 | CYP1A2 525/4885TDP1 4644/4885L3MBTL3 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.